<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852796</url>
  </required_header>
  <id_info>
    <org_study_id>QP2021-PPD</org_study_id>
    <nct_id>NCT04852796</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients</brief_title>
  <acronym>HEMVACO</acronym>
  <official_title>Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de Cornouaille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier de Cornouaille</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported&#xD;
      in December 2019 in Wuhan, China. Infection with this new coronavirus called SARS-CoV-2 can&#xD;
      lead to fatal pneumonia associated with high rates of hospitalization in intensive care units&#xD;
      (ICU).&#xD;
&#xD;
      Hospitalized patients with hematologic malignancies have a higher mortality rate than&#xD;
      patients without hematologic malignancies (62% vs. 8%). The severity of Covid-19 may be&#xD;
      related to their treatment, in particular anti-CD20 used in B lymphoid hemopathies. In fact,&#xD;
      anti-CD20 antibodies induce rapid and prolonged depletion of B cells, but they are necessary&#xD;
      for development. humoral immune responses.&#xD;
&#xD;
      But currently, no immunogenicity data are known for patients with hemopathy or in those on&#xD;
      anti-lymphocyte immunochemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the humoral response after vaccination against&#xD;
      SARS-CoV-2 in a French multicenter cohort of patients with hemopathies. Analysis of&#xD;
      hemopathies and immunochemotherapy subgroups will determine whether there is a need to&#xD;
      strengthen immunization schedules. In addition, the study wish to assess the safety and&#xD;
      clinical efficacy of mRNA vaccines in this cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>humoral response after COVID19 vaccination</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>SARS-CoV-2 Trimeric S IgG titers (BAU/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>humoral response after COVID19 vaccination</measure>
    <time_frame>before first dose vaccination</time_frame>
    <description>SARS-CoV-2 Trimeric S IgG titers (BAU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>humoral response after COVID19 vaccination</measure>
    <time_frame>before second dose vaccination</time_frame>
    <description>SARS-CoV-2 Trimeric S IgG titers (BAU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>humoral response after COVID19 vaccination</measure>
    <time_frame>3 months after vaccination</time_frame>
    <description>SARS-CoV-2 Trimeric S IgG titers (BAU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>humoral response after COVID19 vaccination</measure>
    <time_frame>6 months after vaccination</time_frame>
    <description>SARS-CoV-2 Trimeric S IgG titers (BAU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>humoral response after COVID19 vaccination</measure>
    <time_frame>12 months after vaccination</time_frame>
    <description>SARS-CoV-2 Trimeric S IgG titers (BAU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response after COVID19 vaccination</measure>
    <time_frame>12 months after vaccination</time_frame>
    <description>SARS-CoV-2 disease onset in the follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>security of mRNA COVID19 vaccine</measure>
    <time_frame>3 months after vaccination</time_frame>
    <description>side effects onset in the follow-up</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <condition>Hematologic Malignancy</condition>
  <condition>Vaccine Response Impaired</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with hemopathy</intervention_name>
    <description>optimal humoral response at 1 month after COVID-19 vaccination</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hemopathy followed in declared hospitals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Benign or malignant hemopathy&#xD;
&#xD;
          -  With priority vaccination indication&#xD;
&#xD;
          -  Having benefited from anti-covid-19 mRNA vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under legal protection&#xD;
&#xD;
          -  Palliative care patients&#xD;
&#xD;
          -  History of known Covid-19 disease (&lt;1 year)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LENAIG LE CLECH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Quimper Cornouaille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LENAIG LE CLECH, PhD</last_name>
    <phone>+33298526731</phone>
    <email>l.leclech@ch-cornouaille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MELANIE GUEGUEN, APN</last_name>
    <phone>+33298526433</phone>
    <email>melanie.gueguen@ch-cornouaille.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de Quimper Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LENAIG LE CLECH, PhD</last_name>
      <phone>+33298526731</phone>
      <email>l.leclech@ch-cornouaille.fr</email>
    </contact>
    <contact_backup>
      <last_name>MELANIE GUEGUEN, APN</last_name>
      <phone>+33298526433</phone>
      <email>melanie.gueguen@ch-cornouaille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>LENAIG LE CLECH, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>RONAN LE CALLOCH, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>KRISTELL MAHE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PASCAL HUTIN, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARIE JEANNE RIZCALLAH, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MELANIE GUEGUEN, APN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>JEREMY KERAEN, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PASCAL GODMER, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ADRIEN TREBOUET, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>NADIA SAIDANI, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>LYDIE KAHTCHATOURIAN, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>IAN DORVAL, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARIE SARAH FANGOUS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

